Claims
- 1. A propylamine of the following formula (I): ##STR6## wherein R.sup.1, R.sup.2 and R.sup.3 are lower alkyl groups;
- m is 0 or 1;
- A represents the atoms necessary to form a pyrrolidine, piperidine or morpholine ring;
- Y is independently selected from the group consisting of halo, alkyl, alkoxy, trifluoromethyl, hydroxy, or, when n is 2 on adjacent carbons, methylenedioxy;
- n is 0, 1, 2 or 3; and
- B represents the atoms necessary to a saturated carbocyclic ring;
- and the pharmaceutically acceptable acid addition salts thereof.
- 2. The propylamine of claim 1, wherein
- R.sup.1, R.sup.2 and R.sup.3 are lower alkyl groups of about 1 to 6 carbons each;
- m is 0 or 1;
- A represents the atoms necessary to form a pyrrolidine ring;
- Y is fluoro, chloro, bromo, iodo, alkyl of about 1 to 6 carbons, alkoxy of about 1 to 6 carbons, trifluoromethyl, hydroxy or methylenedioxy;
- n is 0, 1, 2 or 3; and
- B represents the atoms necessary to form a 5- or 6-membered saturated carbocyclic ring.
- 3. The propylamine of claim 2, wherein
- R.sup.1, R.sup.2 and R.sup.3 are each methyl;
- m is 1;
- Y is chloro, methyl, methoxy or trifluoromethyl; and
- B represents the atoms necessary to form a cyclohexyl ring.
- 4. The propylamine of claim 1, wherein n is 2, Y is chloro, methyl, methoxy or trifluoromethyl.
- 5. The propylamine of claim 4, wherein Y is chloro at the 2 and 6 positions.
- 6. The propylamine of claim 1, wherein R.sup.1 and R.sup.3 are each methyl.
- 7. The propylamine of claim 1, wherein R.sup.1 is lower alkyl.
- 8. The propylamine of claim 1, wherein said propylamine is the R isomer with respect to the carbon marked by the asterisk (*).
- 9. The propylamine of claim 1, wherein said propylamine is the S isomer with respect to the carbon marked by the asterisk (*).
- 10. The propylamine of claim 1, wherein said pharmaceutically acceptable acid addition salt is one formed with acids such as hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, a phosphoric, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benzenesulfonic, p-toluene sulfonic, cyclohexanesulfamic, salicylic, p-aminosalicylic, 2-phenoxybenzoic, 2-acetoxybenzoic or a salt made with saccharin.
- 11. The propylamine of claim 1, wherein said propylamine is N-(cyclohexylmethyl)-N-(2,6-dichlorophenyl)-beta-[(2,2-dimethylpropoxy)methyl]-1-pyrrolidineethanamine; or a pharmaceutically acceptable acid addition salt thereof.
- 12. The propylamine of claim 10, wherein said salt is the hydrochloride salt.
- 13. A pharmaceutical composition which comprises a propylamine of claim 1 in association with a pharmaceutically acceptable diluent or carrier.
- 14. A method for the treatment of hypertension in a mammal which comprises administering to the mammal the composition of claim 13.
- 15. The method of claim 14, wherein said mammal is a human.
- 16. A method for the treatment of angina in a mammal which comprises administering to the mammal the composition of claim 13.
- 17. The method of claim 16, wherein said mammal is a human.
Parent Case Info
This application is a division of U.S. Ser. No. 828,923 filed Feb. 12, 1986, now U.S. Pat. No. 4,727,072.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
RE30577 |
Busch et al. |
Apr 1981 |
|
3962238 |
Mauvernay et al. |
Jun 1976 |
|
4430338 |
Jansen et al. |
Feb 1984 |
|
4555514 |
Combourieu et al. |
Nov 1985 |
|
4645778 |
Monteil et al. |
Feb 1987 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
828923 |
Feb 1986 |
|